






## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>A61K 31/445, 31/505</b>	A1	(11) International Publication Number: <b>WO 93/14758</b> (43) International Publication Date: 5 August 1993 (05.08.93)
(21) International Application Number: <b>PCT/DK93/00021</b>		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).
(22) International Filing Date: 22 January 1993 (22.01.93)		
(30) Priority data: 0084/92 23 January 1992 (23.01.92) DK		
(71) Applicant (for all designated States except US): H. LUND-BECK A/S [DK/DK]; Ottiliavej 9, DK-2500 Copenhagen-Valby (DK).		Published With international search report.
(72) Inventors; and		
(75) Inventors/Applicants (for US only) : ANDERSEN, Kim [DK/DK]; Minervavej 11, DK-2610 Rødovre (DK). SKARSFELDT, Torben [DK/DK]; D, Gl.Køge Landevej, DK-2660 Brøndby Strand (DK).		
(74) Agent: MEIDAHL PETERSEN, John; H. Lundbeck A/S, 9, Ottiliavej, DK-2500 Copenhagen-Valby (DK).		

(54) Title: USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES



## (57) Abstract

3-Arylindole or 3-arylindazole derivatives having general formula (I) wherein Ar is optionally substituted phenyl or a hetero aromatic group; R<sup>1</sup>-R<sup>4</sup> are hydrogen, halogen, alkyl, alkoxy, hydroxy, alkylthio, alkylsulfonyl, alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoromethylthio; X is N, CR<sup>6</sup>, R<sup>6</sup> being H, halogen, trifluoromethyl or alkyl, or CH<sub>2</sub>; Y is N, CH or C; R<sup>5</sup> is H, alkyl, alkenyl, cycloalkyl, or cycloalkylalkyl, or R<sup>5</sup> is a substituent of formula (1a) or (1b), wherein n is 2-6; W is O or S; U is N or CH; Z is -(CH<sub>2</sub>)<sub>m</sub>, -CH=CH-, phenylene, -COCH<sub>2</sub>, or -CSCH<sub>2</sub>; V is O, S, CH<sub>2</sub> or NR<sup>7</sup> wherein R<sup>7</sup> is H, alkyl, alkenyl, cycloalkyl or cycloalkylalkyl; U<sup>1</sup> is O, S, CH<sub>2</sub> or NR<sup>8</sup>; and V<sup>1</sup> is NR<sup>9</sup>R<sup>10</sup>, OR<sup>11</sup>, SR<sup>12</sup> or CR<sup>13</sup>R<sup>14</sup>R<sup>15</sup>, where each of R<sup>8</sup>-R<sup>15</sup> are as defined for R<sup>7</sup>; inhibit the firing of spontaneously active dopamine neurones in the ventral tegmental area of the brain and are thus useful for the treatment of psychoses in humans.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Mongeo	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses.

## FIELD OF THE INVENTION

5

The present invention relates to the use of a certain class of 3-arylindole and 3-arylindazole derivatives or salts thereof for the manufacture of a pharmaceutical preparation for the treatment of psychoses.

10

## BACKGROUND OF THE INVENTION

Damping of dopamine (DA) overactivity by the use of DA receptor blocking drugs is today the most important principle in the treatment of schizophrenia, more particularly the positive symptoms thereof. "Classical neuroleptics" such as haloperidol, 15 cis(Z)-flupentixol or chlorpromazine are believed to induce antipsychotic effect via DA receptor blockade. Pharmacologically, such compounds antagonize stereotypies induced by dopaminergic compounds (i.e. methylphenidate, apomorphine, amphetamine) in mice or rats and they inhibit pergolide-induced circling behavior in rats with unilateral 6-OHDA lesions. Unfortunately, the incidence of severe extrapy- 20 ramidal side effects (EPS) (dystonia, akathisia and parkinsonism) is very frequent in long term treatment with these neuroleptics and causes great concern among clinicians. The EPS are difficult to treat, and unsuccessful treatment often leads to poor medication compliance. Some of these neurological side effects, which generally involve involuntary movement disorders, have been correlated to the 25 propensity of the drugs to induce catalepsy in rats (Arnt. et al., *Neuropharmacology*, 1981, 20, 1331-1334).


A few compounds, which do not produce EPS and which are effective in the treatment of schizophrenic disorders, are termed "atypical neuroleptics". Clozapine is 30 such a drug. Clozapine is an effective antipsychotic in man but, due to the risk of drug induced agranulocytosis, regular monitoring of blood parameters is required, and its use is therefore costly and restricted. Pharmacologically, clozapine induces no catalepsy in rats, neither does it inhibit stereotypies induced by dopaminergic

compounds in rodents. Clozapine blocks central cholinergic, serotonergic and noradrenergic receptors in animal studies.

- In recent years several reports have suggested that inhibition of the spontaneous activity of DA neurones in the *ventral tegmental area* (VTA) in the rat brain upon repeated treatment with a drug is indicative of the antipsychotic potential of the drug, whereas inhibition of the activity in *substantia nigra pars compacta* (SNC) is indicative of the development of EPS. "Classical neuroleptics" are active in both areas in the same dose range while "atypical neuroleptics" mainly inactive DA neurons in the VTA. Clozapine has been shown to be active only in the VTA (Bunney and Grace, *Life Science*, 1978, 25, 1715-1725, White and Wang, *Science*, 1983, 221, 1054-1057, Chiodo and Bunney, *J.Neuroscience*, 1985, 5, 2539-2544, Skarsfeldt, *Life Science*, 1988, 42, 1037-1044).
- 15 U.S.Patent No. 4,710,500, corresponding to European Patent No. 0200322, discloses a class of optionally 5-substituted 1-aryl-3-piperidinyl, 1-aryl-3-(1,2,3,6-tetrahydropyridinyl)- or 1-aryl-3-piperazinylindole derivatives having potent 5-HT<sub>2</sub> antagonistic activity, and many of them additionally having potent DA D<sub>2</sub>-antagonistic activity *in vivo*. Previously, one of the compounds known from said patent, i.e. sertindole, 5-chloro-1-(4-fluorophenyl)-3-[1-[2-(2-imidazolidinon-1-yl)-ethyl]-4-piperidyl]-1H-indole, which is a 5-HT<sub>2</sub> antagonist substantially without DA D<sub>2</sub>-antagonistic activity *in vivo*, was surprisingly found to inhibit the firing of DA neurones in the VTA of the brain (cf. our own EP-A1-0392959). However, said patent publication also shows that other very closely related 5-HT<sub>2</sub> antagonists known from U.S.Patent No. 4,710,500 do not inhibit the firing of DA neurones.

Our own copending European Patent Application No. 91610058.9 published as EP-A2-0 470 039 discloses a class of 3-aryllindole or 3-aryllindazole derivatives having the general Formula I

3



wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, and cyano, or Ar is

5 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R<sup>1</sup>-R<sup>4</sup> are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, lower alkylthio, lower alkylsulphonyl, lower alkylamino, di-lower-alkylamino, cyano, trifluoromethyl, and trifluoromethylthio;

10

the dotted lines designate optional double bonds;


when the dotted line emanating from X indicates a double bond, X is N or a group CR<sup>6</sup> wherein R<sup>6</sup> is hydrogen, halogen, trifluoromethyl or lower alkyl; and when the dotted line indicates no double bond, X is CH<sub>2</sub>;

15


when the dotted line emanating from the Y do not indicate a double bond, Y is N or CH; and when it indicates a double bond, then Y is C;

R<sup>5</sup> is hydrogen, or cycloalkyl, cycloalkylalkyl, lower alkyl or lower alkenyl, optionally

20 substituted with one or two hydroxy groups, or R<sup>5</sup> is a group taken from structures 1a and 1b :



or



1b.

wherein n is an integer from 2 - 6, inclusive;

25 W is O or S;

U is N or CH ;

Z is -(CH<sub>2</sub>)<sub>m</sub>-, m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is -CH=CH-, -COCH<sub>2</sub>- or -CSCH<sub>2</sub>-;

V is O, S, CH<sub>2</sub>, or NR<sup>7</sup>, wherein R<sup>7</sup> is hydrogen, lower alkyl, lower alkenyl, cyclo-  
5 alkyl or cycloalkylalkyl optionally substituted with one or two hydroxy groups;

U<sup>1</sup> is O, S, CH<sub>2</sub> or a group NR<sup>8</sup>, wherein R<sup>8</sup> is H, lower alkyl, lower alkenyl, cycloalkyl or cycloalkylalkyl optionally substituted with one or two hydroxy groups;  
and

V<sup>1</sup> is NR<sup>9</sup>R<sup>10</sup>, OR<sup>11</sup>, SR<sup>12</sup> or CR<sup>13</sup>R<sup>14</sup>R<sup>15</sup>, where each of R<sup>9</sup>-R<sup>15</sup> may be indepen-  
10 dently selected among the R<sup>8</sup>-substituents;

provided that R<sup>5</sup> may not be methyl when R<sup>1</sup>-R<sup>4</sup> each are hydrogen, X and Y are CH and Ar is phenyl.

In our EP-A2-0 470 039 the compounds having the above general Formula I were  
15 disclosed as highly potent 5-HT<sub>2</sub> antagonists having a long duration of action in pharmacological tests and accordingly, as useful in the treatment of anxiety, depression, sleep disturbances, migraine, negative symptoms of schizophrenia, and Parkinson's disease. Furthermore, they were found to be substantially without affinity for DA D<sub>2</sub> receptors *in vitro* and to be substantially inactive with respect to  
20 acute dopamine antagonistic effect *in vivo*. The tests used were:

- a) Inhibition of <sup>3</sup>H-ketanserin binding to 5-HT<sub>2</sub> receptors in rat cortex *in vitro*, which is a test for affinity of drugs for 5-HT<sub>2</sub> receptors *in vitro*.
- b) Quipazine antagonism which is a test for 5-HT<sub>2</sub> antagonistic effect *in vivo* based on testing of the ability of drugs to inhibit quipazine-induced head twitches in rats.
- c) Inhibition of <sup>3</sup>H-spiperone binding to DA D<sub>2</sub> receptors in rat corpus striatum *in vitro* which is a test for affinity of drugs for DA D<sub>2</sub> receptors *in vitro*.
- d) Antagonism of pergolide-induced circling behavior in rats with unilateral 6-OHDA lesions which is an extremely sensitive test for acute central DA antagonistic effect *in vivo*.

30

Since it is known that affinities of antipsychotic drugs for 5-HT<sub>2</sub> receptors do not correlate to effects on positive symptoms of schizophrenia (Peroutka, S.J. and Snyder, S.H.: Relationship of neuroleptic drug effects at brain dopamine, serotonin,

alpha-adrenergic, and histamine receptors to clinical potency, Am. J. Psychiatry, 1980, 137, 1518-1522) they were found to be without antipsychotic effects.

## SUMMARY OF THE INVENTION

5

Surprisingly, it has now been found that the 3-arylindole or 3-arylindazole derivatives having the above general Formula I inhibits the firing of DA neurones in the VTA in rats.

- 10 Accordingly, the present invention provides the use of a compound having the above defined general Formula I or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a pharmaceutical composition for the treatment of psychosis in humans.
- 15 The use of stereoisomers and prodrugs of the 3-arylindole or 3-arylindazole derivatives of Formula I are also embraced by this invention.

In the context of the present invention and the definition of Formula I the terms lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl designate such straight chained or branched groups having from one to four carbon atoms inclusive. Exemplary of such groups are methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-propyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, methylthio, ethylthio, 1-propylthio, 2-propylthio, methylsulfonyl, ethylsulphonyl, or the like.

25

Lower alkenyl is intended to mean an alkenyl group containing from 2 to 4 carbon atoms, for example ethenyl, 1-propenyl, 2-but enyl, etc.

Cycloalkyl is such a group comprising 3-8 carbon atoms, cycloalkylalkyl is cyclo-30 alkyl-lower-alkyl, and halogen means fluoro, chloro, bromo or iodo.

The Z groups -COCH<sub>2</sub>- and -CSCH<sub>2</sub>- may be incorporated in the ring of the structure 1a in both directions.

The psychoses to be treated are psychosis in connection with schizophrenia (positive symptoms of schizophrenia) and other psychoses and related disorders, such as mania etc.

5

An effective daily dose of the compound of the invention, or a pharmaceutically acceptable salt thereof, is from 0.01 to 10.0 mg/kg. The daily dose is administered in one or more subdoses and, accordingly, a unit dose of the compound or of the salt thereof is from 0.10 to 200 mg.

10

The compositions of the invention may exist in forms to be administered orally or parenterally, for example in the form of tablets, capsules, powders, syrups or solutions for injection.

15 Preferred compounds used according to the invention are:

3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole, Comp. 1,

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole, Comp. 2,

20 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-5-trifluoromethyl-1*H*-indole, Comp. 3, and

1-[1-[2-(1,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-5-fluoro-3-(4-fluorophenyl)-1*H*-indole, Comp. 4 (mp: 255-57°C as hydrochloride).

25 Further examples of compounds of Formula I used according to the invention are listed in our prior EP-A2-0 470 039.

As found by the test for inhibition of pergolide induced rotations in rats with unilateral 6-OHDA lesions in our prior EP-A2-0 470 039, the compounds used in the present invention do not show acute antidopaminergic activity *in vivo* and as shown in the <sup>3</sup>H-spiperone binding test they have substantially no affinity for dopamine receptors *in vitro*. Accordingly, they were believed to be without antipsychotic effects.

However, they have now unexpectedly been found to inhibit the firing of spontaneously active DA neurones in the VTA of the brain upon repeated treatment as measured electrophysiologically, and thus to have antipsychotic potential.

- 5 In particular, the compounds have been found selectively and partially to inhibit the firing of the DA neurones in the VTA substantially without inhibiting the firing of the DA neurones in the SNC area. Since inhibiting effect in the SNC area is indicative of neurological side effects these compounds are believed to be substantially without such side effects. So, they have been demonstrated to be very promising
- 10 drugs for the treatment of psychoses (i.e. positive symptoms of schizophrenia and psychosis of other genesis).

As mentioned above and already shown in our prior EP-A2-0 470 039 the compounds used in the present invention have potent central 5-HT<sub>2</sub> antagonistic activity. Since such activity is indicative of i.a. effect on negative symptoms of schizophrenia and on quality of sleep, the compositions of the invention have the further advantage of alleviating or relieving the negative symptoms of schizophrenia and/or improving the quality of sleep in a schizophrenic patient. Such effects are highly desired in connection with antipsychotic treatment.

20

The compounds of the general Formula I may be synthesized by methods according to our prior EP Patent publication EP-A2-0 470 039.

The pharmaceutically acceptable acid addition salts of the compounds may be formed by reaction with non-toxic organic or inorganic acids in an aqueous miscible solvent, such as acetone or ethanol, and subsequent isolation of the salt by concentration and cooling or by reaction with an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly.

30

Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis methylene-salicylic, methanesulfonic, ethane-disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic,

cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts, which is well known to the art.

In the following the invention is further illustrated by way of examples with references to the drawings in which:

10 Fig. 1 - 4 : Show the inhibiting effect of Compounds Nos 1 - 4, respectively, of the invention on the firing of neurones in the VTA and the SNC areas of the brain, respectively. Compound 1 was given as the oxalate salt and Comp. 4 as the hydrochloride salt.

Fig. 5 : Shows the inhibiting effect of the reference compound clozapine on the 15 firing of neurones in the VTA and the SNC areas of the brain, respectively.

Fig. 6 : Shows the inhibiting effect of the reference compound haloperidol on the firing of neurones in the VTA and the SNC areas of the brain, respectively.

#### PHARMACOLOGICAL TEST METHODS

20 The compounds used in the invention were tested according to reliable and well known pharmacological methods as follows:

#### Inhibition of DA cell firing in VTA and SNC areas

25 This test model is used to examine the effects on spontaneously active DA neurones in VTA and SNC upon repeated oral treatment. Inhibition of the number of active DA neurones in VTA indicates an antipsychotic effect of a compound, while inhibition of the number of active DA neurones in SNC is believed to account for the development of neurological side effects.

30

For further information see Skarsfeldt, T.: Eur. J. Pharmacol. 1988, 145, 239-243, which information is incorporated herein by reference.

Rats weighing 250 g at the start of the experiment are used. After 21 days of oral treatment with test compound, the rats are anaesthetized and mounted in a stereotaxic instrument. Several groups of rats treated with different doses of test compound are used. A hole (3 x 3 mm) is drilled in the skull. Recording of DA neurone activity is performed with a single barrel glass electrode. Eight electrode penetrations are made through VTA and SNC, respectively. Data from the experiments consist of neurone counts which may be regarded as approximately Poisson distributed. The data are expressed as percent active DA neurones of the number of active neurones in non-treated animals. Results are shown in Figs. 1-4.

10

The known substances clozapine and haloperidol were included in the test for comparison purposes. Results for these known substances are shown in Figs. 5-6, respectively.

15 **Results**

As described in our copending European Patent publication EP-A2-0 470 039, the 3-arylindole or 3-aryliindazole derivatives used according to the present invention potently bind to 5-HT<sub>2</sub> receptors with affinities in the nanomolar range (<sup>3</sup>H-20 ketanserin binding test), whereas they were found to have very low affinity for the DA D-2 receptors (<sup>3</sup>H-spiperone binding test). The compounds were found to have potent central 5-HT<sub>2</sub> antagonism *in vivo* with good oral bioavailability and long duration of action (quipazine-inhibition test). Furthermore it was found that the compounds have substantially no central antidopaminergic activity *in vivo* as measured by the inhibition of pergolide-induced rotations in rats with unilateral 6-OHDA lesions, which test is a extremely sensitive test for DA D-2 antagonistic activity *in vivo* (Arnt, J. and J. Hyttel, *J. Neural. Transm.*, 1986, 67, 225-240).

The test for inhibition of the firing of DA neurones in the VTA and SNC, respectively 30 showed that the compounds used in the present invention inhibits the firing in the VTA. As seen from Figs. 1-4 the exemplifying compounds blocked the firing partially in the VTA, whereas they had substantially no activity in the SNC area. From Figs. 5-6 it appears that haloperidol blocks the firing equipotently in both

areas whereas clozapine, like the compounds used according to the invention, blocks the firing partially and selectively in the VTA, though it is only active in high doses.

5

### **FORMULATION EXAMPLES**

Typical examples of formulas for compositions manufactured according to the invention, are as follows:

10

1) Tablets containing 0.5 milligrams of Comp. 1 calculated as the free base:

Comp. 1	0.5 mg
Lactose	18 mg
Potato starch	27 mg
15 Saccharose	58 mg
Sorbitol	3 mg
Talcum	5 mg
Gelatine	2 mg
Povidone	1 mg
20 Magnesium stearate	0.5 mg

2) Tablets containing 5.0 milligrams of Comp. 4 calculated as the free base:

Comp. 4	5.0 mg
Lactose	16 mg
25 Potato starch	45 mg
Saccharose	106 mg
Sorbitol	6 mg
Talcum	9 mg
Gelatine	4 mg
30 Povidone	3 mg
Magnesium stearate	0.6 mg

## 3) Syrup containing per milliliter:

	Comp. 3	10.0 mg
	Sorbitol	500 mg
	Tragacanth	7 mg
5	Glycerol	50 mg
	Methyl-paraben	1 mg
	Propyl-paraben	0.1 mg
	Ethanol	0.005 ml
	Water	ad 1 ml

10

## 4) Solution for injection containing per milliliter:

	Comp. 2	20.0 mg
	Acetic acid	17.9 mg
15	Sterile water	ad 1 ml

## 5) Solution for injection containing per milliliter:

	Comp. 1	50.0 mg
	Sorbitol	42.9 mg
20	Acetic acid	0.63 mg
	Sodium hydroxide	22 mg
	Sterile water	ad 1 ml


Any other pharmaceutical adjuvants may be used provided that they are compatible  
25 with the active ingredient, and additional compositions and dosage forms may be similar to those presently used for neuroleptics, such as clopenthixol, flupentixol or fluphenazine.

Also combinations of the compounds as well as their non-toxic acid salts with other  
30 active ingredients, especially other neuroleptics, thymoleptics, tranquilizers, analgesics or the like, fall within the scope of the present invention.

## CLAIMS

## 1. Use of a 3-arylindole or 3-arylimidazole derivatives having the general Formula I :

5



wherein Ar is phenyl optionally substituted with one or more substituents selected from halogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, and cyano, or Ar is  
10 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

R1-R4 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, lower alkylthio, lower alkylsulphonyl, lower alkylamino, di-lower-alkylamino, cyano, trifluoromethyl, and trifluoromethylthio;

15


the dotted lines designate optional double bonds;

when the dotted line emanating from X indicates a double bond, X is N or a group CR<sup>6</sup> wherein R<sup>6</sup> is hydrogen, halogen, trifluoromethyl or lower alkyl; and when the dotted line indicates no double bond, X is CH<sub>2</sub> ;


20

when the dotted line emanating from the Y do not indicate a double bond, Y is N or CH; and when it indicates a double bond then Y is C;

R<sup>5</sup> is hydrogen, or cycloalkyl, cycloalkyl-lower-alkyl, lower alkyl or lower alkenyl,  
25 optionally substituted with one or two hydroxy groups, or R<sup>5</sup> is a group taken from structures 1a and 1b :



or



1b.

wherein n is an integer from 2 - 6, inclusive;

W is O or S;

5 U is N or CH ;

Z is  $-(\text{CH}_2)_m-$ , m being 2 or 3, or Z is 1,2-phenylene optionally substituted with halogen or trifluoromethyl or Z is  $-\text{CH}=\text{CH}-$ ,  $-\text{COCH}_2-$  or  $-\text{CSCH}_2-$ ;

V is O, S,  $\text{CH}_2$ , or  $\text{NR}^7$ , wherein  $\text{R}^7$  is H, lower alkyl, lower alkenyl, cycloalkyl or cycloalkyl-lower-alkyl optionally substituted with one or two hydroxy groups;

10 U<sup>1</sup> is O, S,  $\text{CH}_2$  or a group  $\text{NR}^8$ , wherein  $\text{R}^8$  is H, lower alkyl, lower alkenyl, cycloalkyl or cycloalkyl-lower-alkyl optionally substituted with one or two hydroxy groups; and

V<sup>1</sup> is  $\text{NR}^9\text{R}^{10}$ ,  $\text{OR}^{11}$ ,  $\text{SR}^{12}$  or  $\text{CR}^{13}\text{R}^{14}\text{R}^{15}$ , where each of R<sup>9</sup>-R<sup>15</sup> may be independently selected among the R<sup>8</sup>-substituents;

15 provided that R<sup>5</sup> may not be methyl when R<sup>1</sup>-R<sup>4</sup> each are H, X and Y are CH and Ar is phenyl;

or a pharmaceutically acceptable acid addition salt or a prodrug thereof, for the manufacture of a pharmaceutical composition for the treatment of psychoses in humans.

20

2. A use according to Claim 1, characterized in that the compound used is selected from:

3-(4-Fluorophenyl)-5-methyl-1-[1-[2-[3-(2-propyl)imidazolidin-2-on-1-yl]ethyl]-4-piperidyl]-1*H*-indole,

25 3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-4-piperidyl]-5-methyl-1*H*-indole,

3-(4-Fluorophenyl)-1-[1-[2-(imidazolidin-2-on-1-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-5-trifluoromethyl-1*H*-indole, and

1-[1-[2-(1,3-Dimethyl-1-ureido)ethyl]-4-piperidyl]-5-fluoro-3-(4-fluorophenyl)-

30 1*H*-indole.

3. A method for the treatment of psychoses in humans comprising the step of administering a therapeutically effective amount of a 3-arylindole or 3-arylindazole derivative having the general Formula I as defined in Claim 1 or a pharmaceutically acceptable acid addition salt or prodrug thereof to a patient in need thereof.
4. A method for the treatment of psychoses in humans comprising the step of administering a therapeutically effective amount of a 3-arylindole or 3-arylindazole derivative as defined in Claim 2 or a pharmaceutically acceptable acid addition salt or prodrug thereof to a patient in need thereof.

1/3

Fig. 1.

Comp. 1





Fig. 2

Comp. 2



2/3

Fig. 3.

## Comp. 3





Fig. 4.

## Comp. 4



3/3

Fig. 5



**Clozapine**

Fig. 6

**Haloperidol**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 93/00021

## A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61K 31/445, A61K 31/505

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPAT, USPM

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP, A2, 0470039 (H. LUNDBECK A/S), 5 February 1992 (05.02.92)  --	1-2
A	US, A, 4710500 (J. K. PERREGAARD), 1 December 1987 (01.12.87)  --	1-2
A	EP, A2, 0392959 (H. LUNDBECK A/S), 17 October 1990 (17.10.90)  -----	1-2

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

21 April 1993

26 -04- 1993

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gomez Lagerlöf  
Telephone No. +46 8 782 25 00

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/DK 93/00021

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 3-4  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
  
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
  
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

31/03/93

International application No.

PCT/DK 93/00021

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A2- 0470039	05/02/92	AU-A-	8141191	06/02/92
		JP-A-	4368367	21/12/92
US-A- 4710500	01/12/87	AU-B-	583607	04/05/89
		CA-A-	1256437	27/06/89
		EP-A,B-	0200322	05/11/86
		SE-T3-	0200322	
EP-A2- 0392959	17/10/90	AU-B-	621735	19/03/92
		AU-A-	5303790	18/10/90
		JP-A-	2290872	30/11/90
		US-A-	5112838	12/05/92